TRALI in a Patient with Hematological Malignancy: Complexities in the Critically IllRajeswari Subramaniyan*
Department of Transfusion Medicine, Yashoda Hospital, Malakpet, Hyderabad, India
- *Corresponding Author:
- Rajeswari Subramaniyan
Department of Transfusion Medicine
Yashoda Hospital, Malakpet
Tel: 040 6777888
Email: [email protected]
Received date: September 16, 2016; Accepted date: September 30, 2016; Published date: October 04, 2016
Citation: Subramaniyan R (2016) TRALI in a Patient with Hematological Malignancy: Complexities in the Critically Ill. J Blood Disord Transfus 7:369. doi:10.4172/2155-9864.1000369
Copyright: © 2016 Subramaniyan R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion related mortality. It is a new lung injury occuring within 6 hours of transfusion having no alternative risk factors of acute lung injury. Here we report a patient with AML-M3, who probably had TRALI after apheresis platelet transfusion and died despite prompt resuscitation. A strong clinical suspicion of TRALI is required. Critically ill patients with hematological malignancies are at risk population for TRALI. TRALI related mortality rate in such patients is significant. TRALI risk mitigation measures should be implemented in this cohort to reduce the incidence.